<DOC>
	<DOCNO>NCT01511809</DOCNO>
	<brief_summary>The study ass whether Atazanavir/ritonavir monotherapy provide non-inferior proportion virological efficacy respect ATV/RTV + 2 NRTIs patient stable suppressed viremia prior virologic failure .</brief_summary>
	<brief_title>Efficacy Atazanavir/Ritonavir Monotherapy Maintenance Patients With Viral Suppression</brief_title>
	<detailed_description>This randomise ( 1:1 ) , multicentre , comparative , parallel-group , prospective , open label , non-inferiority control clinical trial . Enrolled patient , take ATV/r base HAART stable HIV-RNA &lt; 50c/ml ( 24 week ) , randomize : - continue regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs ( accord specific dose schedule ) backbone ( HAART arm ) ATV/r - simplify therapy ATV/RTV 300mg/100mg OD monotherapy ( Monotherapy arm ) ATV/r The study follow 96 week randomization primary objective evaluate week 48 . Patients follow every 4 week first 16 week , every 8 week week 48 , every 12 week week 96 discontinuation ; visit follow evaluation perform : - clinical assessment . - routine laboratory test ( hematological test hematochemistry ) include creatinine , phosphorus , calcium , alkaline phosphatase , gammaGT ; urine analysis , lipid profile , level HIV-RNA CD4 cell count . During follow-up , randomization , week 48 , week 96 discontinuation , patient additionally undergo : - Fat redistribution evaluation DEXA ( dual-energy X-ray absorptiometry - Vertebral femoral bone mineral density evaluation DEXA . - ECG ; - Glicate haemoglobin . - Adherence assessment ( questionnaire and/or pill count ) . - Neurocognitive evaluation [ HIV-associated neurocognitive disorder ( HANDs ) evaluate validated neuropsychological test ] . In case viral rebound ( defined 2 consecutive measurement HIV-RNA &gt; 50 c/ml ) patient immediately contact order perform genotypic test . Furthermore plasma PK analysis also perform . Any patient virological rebound select reintensification therapy NRTIs suppress 12 week discontinue .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>HIV infect patient age &gt; 18 year On treatment ATV/r plus 2 NRTIs least 48 week Virological suppression ( HIVRNA &lt; 50 c/ml ) least 24 week ATV/r plus 2 NRTIs No virologic failure initiation first antiretroviral therapy . Previous treatment change due toxicity treatment simplification permit occur documented virological suppression . CD4 cell nadir &gt; 100 cells/ÂµL PPI H2receptor antagonists follow : protonpump inhibitor use ; H2receptor antagonists coadministered , dose equivalent famotidine 20 mg BID exceed . Pregnancy breast feeding woman AIDS define event Evidence active HBV infection ( HBsAg positive ) Previous virological failure History resistance ATV Use contraindicate medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIV-1</keyword>
</DOC>